N/A N=97 Study on Wood-plastic Composite for Circumferential Casting
Bone Fracture · Radius Fracture · Ankle Fracture
Primary: Efficient Casting With Woodcast Circular System — 90 participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=3,222 Combination Chemotherapy With or Without Trastuzumab in Treating Women With Breast Cancer
Breast Neoplasms
Primary: Percentage of Participants With Disease Free Survival at 5 Years — 75.5; 83.2; 81.0 percentage of participants
N/A N=311 Study Evaluating Changes in Total Drug Load and Seizure Frequency Using Vimpat® (Lacosamide) in Combination Therapy
Focal Epilepsy With and Without Secondary Generalization
Primary: The Percent Change in Ratio of Dose and Defined Daily Dose (DDD) for the Drug Load of Concomitant Anti-Epileptic Drugs (AEDs) From Baseline to the End of Observation…
N/A N=94 Parent Nurse Controlled Analgesic in Pediatric Patients With Developmental Delay
Post Operative Pain
Primary: Median Pain Score During Shift 1, as Measured With the Face, Legs, Activity, Cry, Consolability Scale — 1.0; 1.8; 1.5 units on a scale
Phase 2 N=50 FR901228 in Treating Patients With Recurrent High-Grade Gliomas
Adult Anaplastic Astrocytoma · Adult Anaplastic Oligodendroglioma · Adult Giant Cell Glioblastoma
Primary: Number of Participants With Dose-limiting Toxicities Due to Romidepsin Graded According to the NCI Common Toxicity Criteria (CTCAE Version 3.0) (Phase I) — 0 participants
Phase 2 N=135 Efficacy and Safety of Two Fixed Dose Combinations of Aclidinium Bromide With Formoterol Fumarate
Chronic Obstructive Pulmonary Disease
Primary: Change From Baseline in Normalized Forced Expiratory Volume in 1 Second (FEV1) Area Under the Curve Over 12 Hours (AUC0-12h) After Morning Study Drug Administration at…
Phase 3 N=269 Comparison of Sofosbuvir/Velpatasvir Fixed Dose Combination for 12 Weeks With Sofosbuvir and Ribavirin for 12 Weeks in Adults With Chronic Genotype 2 HCV Infection
Hepatitis C Virus Infection
Primary: Percentage of Participants With Sustained Virologic Response (SVR) 12 Weeks After Discontinuation of Therapy (SVR12) — 99.3; 93.9 percentage of participants — p=0.018
N/A N=41 Tolerance Evaluation of a Nighttime Moisturizing Balm on Babies and Adults With Eczema
Atopic Dermatitis (AD)
Primary: Percentage With Erythema on the Face at Baseline Before Investigational Product Application — 33.3; 71.9; 55.6; 6.3 Percentage of participants
Phase 2 N=45 Effects of Sulforaphane on Normal Prostate Tissue
Prostate Cancer
Primary: Gene Expression of Phase II Enzymes — -0.36; 0.26; 0.15; -0.59 -fold change in expression
N/A N=120 Prevention of Lymphoceles After Robotic PLND
Lymphoceles · Prostate Cancer
Primary: Incidence of Lymphoceles — 10; 12; 104; 102 participants — p=0.412
Phase 3 N=40 Evaluation of Green Tea as Antioxidant Agent in Management of Oral Lichen Planus
Oral Lichen Planus
Primary: Pain — 0; 4; 4.4 units on a scale
Phase 4 N=67 Medical Therapy Versus Radiofrequency Endometrial Ablation in the Initial Treatment of Menorrhagia
Menorrhagia
Primary: Menstrual Blood Loss (MBL) as Measured by Pictorial Blood Loss Assessment Chart (PBLAC). — 15; 0 units on a scale — p=0.003
Phase 2 N=24 Phase II Study of Irinotecan and Panitumumab
Esophageal Cancer
Primary: Response Rate (RR) — 6 percentage of participants
Phase 4 N=829 Efficacy and Safety of Coumarin and Troxerutin in the Symptomatic Treatment of Chronic Venous Insufficiency
Chronic Venous Insufficiency
Primary: Mean Change (Reduction) From Baseline in Volume of Reference Leg at Week 16 — 1.13; 5.78 milliliters (mL) — p=0.531
Phase 3 N=1,891 CPG Styles Study: A Study of the Safety of the Contour Profile Gel Breast Implants (CPG Styles Study)
Breast Augmentation · Breast Reconstruction · Breast Revision
Primary: 6-Year Kaplan-Meier Estimated Cumulative Incidence Rate of Occurrence of Any Reoperation — 8.3; 31.7; 13.8; 31.3 percentage of subjects